儿童接受肿瘤坏死因子α抑制剂后出现矛盾性银屑病样皮疹
这项多中心回顾性病例系列分析了2000年至2016年间103例因非皮肤疾病使用TNF抑制剂后新发银屑病样皮疹的儿童,中位潜伏期14.5个月,多数患者局部治疗有效并可继续TNF抑制剂治疗。
要点
- 儿童TNF抑制剂诱导的银屑病样皮疹多在用药后14.5个月出现,头皮最常受累。
- 大多数患儿仅需局部治疗,29%需加用系统治疗,25%因局部疗效不佳而更换TNF抑制剂。
- 更换TNF抑制剂后88%患儿皮疹改善,但31%再发矛盾性皮疹。
核心结论
- 儿童因任何适应症使用TNF抑制剂均可出现矛盾性银屑病样皮疹,不同TNF抑制剂之间似乎存在类效应。
- 多数患儿通过充分的皮肤导向治疗和其他辅助治疗得以继续TNF抑制剂治疗。
研究设计与样本
- 多中心回顾性病例系列,纳入2000年1月1日至2016年12月31日期间年龄小于18岁、因非皮肤疾病使用TNF抑制剂后新发银屑病样皮疹的儿童,参与中心为儿科皮肤病研究联盟成员,数据录入Mayo Clinic协调的研究电子数据采集数据库。
主要发现
- 共纳入103例TNF抑制剂治疗的银屑病样皮疹患者,中位年龄13.8岁(IQR 11.7-16.4岁),女性52例(50%),白人57例(55%)。
- 67例(65%)使用英夫利西单抗,35例(34%)使用阿达木单抗,1例(1%)使用培塞利珠单抗。
- 101例(98%)无个人银屑病史,60例(58%)无家族银屑病史;94例(91%)因炎症性肠病使用TNF抑制剂;95例(92%)原发皮肤外疾病控制良好。
- 85例(83%)皮疹累及多个解剖部位,头皮最常受累(65例,63%);皮疹在TNF抑制剂启动后中位14.5个月(IQR 9-24个月)出现。
- 所有患者均接受局部类固醇和非类固醇药物治疗;30例(29%)加用系统治疗:甲氨蝶呤24例(23%)、口服糖皮质激素8例(8%)、硫唑嘌呤1例(1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tumor necrosis factor α (TNF) inhibitor-induced psoriasiform eruption is well recognized in adults, but few reports document this paradoxical effect in children. OBJECTIVE: To characterize the clinical features and the clinical time course of TNF inhibitor-induced psoriasiform eruptions in children. DESIGN, SETTING, AND PARTICIPANTS: A multicenter retrospective case series of children younger than 18 years seen between January 1, 2000, and December 31, 2016, who developed a new-onset psoriasiform eruption while taking a TNF inhibitor for a nondermatologic disorder. Participating sites were members of the Pediatric Dermatology Research Alliance. Data were entered into a Research Electronic Data Capture database at the Mayo Clinic (ie, the coordinating center). RESULTS: Psoriasiform eruptions were identified in 103 TNF inhibitor-treated patients (median age, 13.8 years [IQR, 11.7-16.4 years]; 52 female patients [50%]; 57 White patients [55%]), with 67 patients (65%) treated with infliximab, 35 (34%) with adalimumab, and 1 (1%) with certolizumab pegol. Most patients had no personal history (101 [98%]) or family history of psoriasis (60 patients [58%]). Inflammatory bowel disease was the most common indication for treatment with TNF inhibitor (94 patients [91%]). The primary extracutaneous disease was under control in 95 patients (92%) who developed the eruption. Most patients (n = 85 [83%]) developed psoriasiform eruptions at multiple anatomic sites, with scalp involvement being most common (65 patients [63%]). Skin disease developed at a median of 14.5 months (IQR, 9-24 months) after TNF inhibitor initiation. To treat the psoriasiform eruption, topical steroidal and nonsteroidal medication was prescribed for all patients. Systemic therapy was added for 30 patients (29%): methotrexate for 24 patients (23%), oral corticosteroids for 8 patients (8%), and azathioprine for 1 patient (1%). For 26 patients (25%), suboptimal effectiveness with topical medications alone prompted discontinuation of the initial TNF inhibitor and a change to a second-line TNF inhibitor with cutaneous improvement in 23 patients (88%) by a median of 3 months (IQR, 2-4 months). Eight patients (31%) who started a second-line TNF inhibitor developed a subsequent TNF inhibitor-induced psoriasiform eruption at a median of 6 months (IQR, 4-8 months). Persistent skin disease in 18 patients (17%) prompted discontinuation of all TNF inhibitors; 11 patients changed to a non-TNF inhibitor systemic therapy, and 7 discontinued all systemic therapy. CONCLUSIONS AND RELEVANCE: In this case series, paradoxical TNF inhibitor-induced psoriasiform eruptions were seen in children treated with TNF inhibitors for any indication, and there appears to be a class effect among the varying TNF inhibitors. The majority of these children were able to continue TNF inhibitor therapy with adequate skin-directed and other adjuvant therapies.
引用
- Eickstaedt J, Paller AS, Lund E, et al. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors. JAMA Dermatol. 2023. PMID: 37043214. doi:10.1001/jamadermatol.2023.0549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。